Do CFH rs1061170 and C3 rs2230199 variants predispose to excessive complement activation?

The alternative complement pathway (AP) serves as a critical first-line defense system that relies on a delicate balance between spontaneous activation and regulatory control. Genetic variants in the CFH and C3 genes are well-documented to disrupt this equilibrium, predisposing individuals to systemic and tissue-specific inflammation.

Mechanistic evidence

The dysregulation caused by these variants occurs through a "loss of brakes" and a "stuck throttle" mechanism within the complement cascade:

• CFH rs1061170 (Y402H): This variant involves a tyrosine-to-histidine substitution at position 402 of Complement Factor H (CFH). CFH is the primary negative regulator of the alternative pathway. The 402H risk allele specifically impairs the ability of CFH to bind to host cell surfaces, C3b, and oxidation-specific epitopes like malondialdehyde. This reduction in binding affinity diminishes CFH’s capacity to act as a cofactor for Factor I-mediated cleavage of C3b and reduces its "decay-accelerating activity" (DAA), which normally breaks down the AP C3 convertase (C3bBb).
• C3 rs2230199 (R102G): This variant functions as a gain-of-function mutation. It increases the resistance of C3b to inactivation by Factor I and enhances its binding affinity for Factor B. This stabilization of the C3 convertase ensures that the AP amplification loop remains active for longer periods, driving higher rates of C3 consumption and opsonization.

Clinical and effectiveness evidence

The synergy between these variants leads to measurable excessive complement activation and downstream opsonization:

• Systemic Markers: Dysregulation is characterized by the accumulation of activation products. Clinical studies show that individuals with these variants often exhibit elevated levels of soluble C5b-9 (the terminal membrane attack complex) and significant consumption (depletion) of plasma C3.
• Pathogenic Outcomes: This unchecked amplification is a primary driver in several complement-mediated diseases. The CFH Y402H variant is most famously linked to a significantly increased risk of age-related macular degeneration (AMD). Simultaneously, these variants contribute to the pathogenesis of atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G), where excessive C3 deposits are observed in the glomerular basement membrane of the kidneys.

Bottom line

The CFH rs1061170 and C3 rs2230199 variants are scientifically validated to cause alternative pathway dysregulation. By impairing regulatory binding and stabilizing the C3 convertase, these variants create a genetic predisposition to excessive complement activation and subsequent tissue damage.